Efficacy classification of modern therapies in multiple sclerosis
The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. Therapies were classified by...
Saved in:
| Published in | Journal of comparative effectiveness research Vol. 10; no. 6; pp. 495 - 507 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Future Medicine Ltd
01.04.2021
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2042-6305 2042-6313 2042-6313 |
| DOI | 10.2217/cer-2020-0267 |
Cover
| Abstract | The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines.
Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate.
For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used.
Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy. |
|---|---|
| AbstractList | Background: The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. Materials & methods: Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate. Results: For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used. Conclusion: Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy.Background: The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. Materials & methods: Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate. Results: For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used. Conclusion: Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy. Background: The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. Materials & methods: Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate. Results: For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used. Conclusion: Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy. Background: The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. Materials & methods: Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate. Results: For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used. Conclusion: Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy. The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate. For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used. Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy. |
| Author | Häring, Dieter A Drudge, Christopher Stoneman, Dee Klotz, Luisa Adlard, Nicholas Cameron, Chris Samjoo, Imtiaz A Worthington, Evelyn Zhao, Melody |
| AuthorAffiliation | 4Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany 3Novartis Pharma AG, Basel, Switzerland 1EVERSANA™, Burlington, ON, Canada 2EVERSANA™, Sydney, NS, Canada |
| AuthorAffiliation_xml | – name: 1EVERSANA™, Burlington, ON, Canada – name: 3Novartis Pharma AG, Basel, Switzerland – name: 4Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany – name: 2EVERSANA™, Sydney, NS, Canada |
| Author_xml | – sequence: 1 givenname: Imtiaz A orcidid: 0000-0003-1415-8055 surname: Samjoo fullname: Samjoo, Imtiaz A organization: EVERSANA™, Burlington, ON, Canada – sequence: 2 givenname: Evelyn orcidid: 0000-0003-1659-2082 surname: Worthington fullname: Worthington, Evelyn organization: EVERSANA™, Burlington, ON, Canada – sequence: 3 givenname: Christopher orcidid: 0000-0001-9721-3069 surname: Drudge fullname: Drudge, Christopher organization: EVERSANA™, Burlington, ON, Canada – sequence: 4 givenname: Melody orcidid: 0000-0002-3891-5367 surname: Zhao fullname: Zhao, Melody organization: EVERSANA™, Burlington, ON, Canada – sequence: 5 givenname: Chris orcidid: 0000-0003-3613-760X surname: Cameron fullname: Cameron, Chris organization: EVERSANA™, Sydney, NS, Canada – sequence: 6 givenname: Dieter A surname: Häring fullname: Häring, Dieter A organization: Novartis Pharma AG, Basel, Switzerland – sequence: 7 givenname: Dee surname: Stoneman fullname: Stoneman, Dee organization: Novartis Pharma AG, Basel, Switzerland – sequence: 8 givenname: Luisa surname: Klotz fullname: Klotz, Luisa organization: Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany – sequence: 9 givenname: Nicholas orcidid: 0000-0001-6912-1685 surname: Adlard fullname: Adlard, Nicholas organization: Novartis Pharma AG, Basel, Switzerland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33620251$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kDtPwzAURi0EolAYWVEkFpaA34nHqioPqRILzJbj3AijxAl2MvDvcSgwVKoX-8rns-895-jY9x4QuiL4jlJS3FsIOcUU55jK4gidUcxpLhlhx_9nLBboMsYPnJYsuRL0FC0YkykmyBlabZrGWWO_MtuaGN1cjK73Wd9kXV9D8Nn4DsEMDmLmfNZN7eiGFrJoWwh9dPECnTSmjXD5uy_R28Pmdf2Ub18en9erbW45wWNe8pIUhIFSvOEFrioCIKWVhaBCkrIGISWtS8GqxpSVVaU0ililynTHuBVsiW537w6h_5wgjrpz0ULbGg_9FDXlikpJCjGjN3voRz8Fn7rTaWiR_mS8SNT1LzVVHdR6CK4z4Uv_yUlAvgNsGjQGaP4RgvXsXyf_evavZ_-JZ3u8deOPzTEY1x5MqV2qmcYpQLQOvAW9q1JfzjoPB7Lf9PCZ5g |
| CitedBy_id | crossref_primary_10_1016_j_msard_2024_105547 crossref_primary_10_1007_s40120_021_00320_w crossref_primary_10_1177_13524585231157206 crossref_primary_10_1007_s10072_023_07282_x crossref_primary_10_1016_j_msard_2023_104770 crossref_primary_10_1016_j_msard_2022_104456 crossref_primary_10_1039_D1MD00131K crossref_primary_10_1093_ajhp_zxad247 crossref_primary_10_1080_13696998_2022_2151270 crossref_primary_10_1016_j_msard_2024_105828 crossref_primary_10_1002_acn3_52198 crossref_primary_10_1177_13524585231213230 crossref_primary_10_1590_0004_282x_anp_2022_s128 crossref_primary_10_1155_2024_7808140 crossref_primary_10_1212_WNL_0000000000210004 crossref_primary_10_1177_13524585231221411 crossref_primary_10_1186_s12974_023_02859_x crossref_primary_10_1007_s41669_022_00381_z crossref_primary_10_2217_fnl_2023_0009 crossref_primary_10_1038_s41598_024_64713_1 crossref_primary_10_1016_j_intimp_2024_111826 crossref_primary_10_1002_cpt_3492 crossref_primary_10_1177_13524585221111684 crossref_primary_10_1038_s41598_025_87827_6 crossref_primary_10_3390_ijerph19095038 crossref_primary_10_1007_s00415_024_12729_y crossref_primary_10_1007_s43440_024_00642_0 crossref_primary_10_1080_17512433_2025_2481868 crossref_primary_10_1007_s40120_023_00549_7 crossref_primary_10_1080_1028415X_2023_2201026 crossref_primary_10_1080_13696998_2022_2161746 crossref_primary_10_1177_13524585231225929 crossref_primary_10_1016_j_msard_2023_104708 crossref_primary_10_7759_cureus_45454 crossref_primary_10_1002_ana_27093 crossref_primary_10_1177_08980101241292099 crossref_primary_10_1007_s40120_023_00573_7 crossref_primary_10_2217_cer_2021_0249 crossref_primary_10_1007_s40120_023_00518_0 crossref_primary_10_1016_j_msard_2024_105888 crossref_primary_10_1038_s41582_024_01050_x crossref_primary_10_1007_s10072_022_06197_3 crossref_primary_10_1016_j_msard_2024_105688 crossref_primary_10_1177_20503121231171996 crossref_primary_10_26565_2312_5675_2024_25_05 crossref_primary_10_1016_j_msard_2025_106334 crossref_primary_10_3390_ph17080983 crossref_primary_10_1007_s40120_024_00707_5 crossref_primary_10_1038_s41598_024_65575_3 crossref_primary_10_2147_PPA_S440410 crossref_primary_10_1016_j_msard_2022_103985 crossref_primary_10_1186_s12883_024_03643_x crossref_primary_10_1002_acn3_52253 crossref_primary_10_3897_pharmacia_71_e117681 crossref_primary_10_1177_13524585221109386 crossref_primary_10_1007_s00415_024_12305_4 crossref_primary_10_1007_s00415_023_12132_z crossref_primary_10_1177_13524585241228423 crossref_primary_10_1007_s40801_023_00387_x crossref_primary_10_1007_s40120_023_00523_3 crossref_primary_10_1016_j_msard_2022_104393 crossref_primary_10_1016_j_msard_2023_104841 crossref_primary_10_3390_medicina60010006 crossref_primary_10_1016_j_ebiom_2025_105559 crossref_primary_10_1177_13524585231169466 crossref_primary_10_1007_s40120_024_00654_1 crossref_primary_10_1016_j_eclinm_2024_102476 crossref_primary_10_1007_s41669_022_00363_1 crossref_primary_10_3390_children9111698 crossref_primary_10_1080_14737167_2024_2406797 crossref_primary_10_1212_NXI_0000000000200377 crossref_primary_10_2174_1570159X21666230322140711 crossref_primary_10_57264_cer_2022_0175 crossref_primary_10_3988_jcn_2022_0208 crossref_primary_10_57264_cer_2023_0026 crossref_primary_10_1007_s00415_022_11193_w crossref_primary_10_1016_j_msard_2025_106263 crossref_primary_10_3390_biomedicines13020266 crossref_primary_10_1007_s40263_024_01116_w crossref_primary_10_1038_s41598_021_97543_6 |
| Cites_doi | 10.1002/jrsm.12 10.1016/S1474-4422(09)70226-1 10.1056/NEJMoa1601277 10.1186/1741-7015-11-159 10.1177/1352458517751049 10.1002/ana.23863 10.1016/S1474-4422(08)70200-X 10.1056/NEJMoa0802670 10.1016/S0140-6736(98)03334-0 10.1007/s40263-018-0541-5 10.1016/S0140-6736(08)61620-7 10.1001/jamaneurol.2014.3537 10.1016/S0149-2918(03)90013-0 10.1016/j.jval.2011.04.002 10.1590/0004-282x20180078 10.1056/NEJM198708133170703 10.1212/01.WNL.0000034080.43681.DA 10.1002/ana.23938 10.1056/NEJMoa044397 10.12998/wjcc.v3.i7.545 10.2217/cer-2020-0122 10.1002/ana.410390304 10.1056/NEJMoa0902533 10.1177/1352458510394702 10.1016/S1474-4422(19)30238-8 10.1212/WNL.45.7.1268 10.1177/0272989X12458724 10.1056/NEJMoa0907839 10.1016/S0140-6736(12)61769-3 10.7326/0003-4819-151-4-200908180-00135 10.1177/1352458513507821 10.1016/j.msard.2018.12.040 10.1056/NEJMoa1206328 10.1212/WNL.0000000000005347 10.1007/s00415-014-7264-4 10.1016/j.jval.2011.01.011 10.1056/NEJMoa1014656 10.1016/S1474-4422(14)70068-7 10.1159/000348701 10.1016/S0140-6736(12)61768-1 10.1056/NEJMoa0909494 10.1212/WNL.0000000000000560 10.1056/NEJMoa1114287 10.1212/WNL.43.4.655 10.1136/practneurol-2015-001139 10.1007/s11055-018-0570-z 10.1080/03007995.2017.1407303 10.1016/S0140-6736(02)08430-1 10.1016/S1474-4422(14)70049-3 10.1177/1756285614555335 10.1016/j.autrev.2017.04.010 10.1016/S1474-4422(13)70308-9 10.1016/S1474-4422(19)30239-X |
| ContentType | Journal Article |
| Copyright | 2021 Chris Cameron 2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2021 Chris Cameron – notice: 2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | FUMOA AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.2217/cer-2020-0267 |
| DatabaseName | Future Medicine (Open Access) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest One Academic Eastern Edition CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: FUMOA name: Future Medicine (Open Access) url: https://www.futuremedicine.com/action/showPublications?pubType=journal sourceTypes: Publisher – sequence: 4 dbid: 7X7 name: ProQuest Health & Medical Collection (NC LIVE) url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2042-6313 |
| EndPage | 507 |
| ExternalDocumentID | 33620251 10_2217_cer_2020_0267 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Network Meta-Analysis |
| GroupedDBID | 0R 4.4 53G 70G 7X7 8FI 8FJ ABUWG ADBBV AENEX AFKRA ALMA_UNASSIGNED_HOLDINGS BBAFP BENPR BPHCQ BVXVI EBS FUMOA FYUFA HZ IAO IHR NTCAX O9- PQEST PQQKQ PROAC RFM AAWTO AAYXX CCPQU CITATION EJD GROUPED_DOAJ H13 HMCUK HZ~ ITC OVD PHGZM RPM TEORI UKHRP ALIPV CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK K9. PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c410t-8481713e994f470bb1ee66c67525618de5662d853bfa8bc986a91c99818d34c53 |
| IEDL.DBID | 7X7 |
| ISSN | 2042-6305 2042-6313 |
| IngestDate | Sun Sep 28 08:07:52 EDT 2025 Sun Jun 29 16:45:53 EDT 2025 Sat Apr 19 01:22:40 EDT 2025 Wed Oct 01 03:07:19 EDT 2025 Thu Apr 24 23:05:03 EDT 2025 Sat Mar 27 13:51:53 EDT 2021 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | ozanimod relapsing multiple sclerosis ocrelizumab cladribine ofatumumab disease-modifying therapy treatment guidelines network meta-analysis |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c410t-8481713e994f470bb1ee66c67525618de5662d853bfa8bc986a91c99818d34c53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-1415-8055 0000-0001-6912-1685 0000-0003-3613-760X 0000-0003-1659-2082 0000-0001-9721-3069 0000-0002-3891-5367 |
| OpenAccessLink | http://dx.doi.org/10.2217/cer-2020-0267 |
| PMID | 33620251 |
| PQID | 2515675347 |
| PQPubID | 3747994 |
| PageCount | 13 |
| ParticipantIDs | proquest_miscellaneous_2492661755 proquest_journals_2515675347 pubmed_primary_33620251 crossref_primary_10_2217_cer_2020_0267 crossref_citationtrail_10_2217_cer_2020_0267 futurescience_futuremedicine_10_2217_cer_2020_0267 |
| ProviderPackageCode | RFM FUMOA NTCAX 70G CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-04-01 |
| PublicationDateYYYYMMDD | 2021-04-01 |
| PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of comparative effectiveness research |
| PublicationTitleAlternate | J Comp Eff Res |
| PublicationYear | 2021 |
| Publisher | Future Medicine Ltd |
| Publisher_xml | – name: Future Medicine Ltd |
| References | Compston A (e_1_3_7_3_2) 2008; 372 Gold R (e_1_3_7_42_2) 2012; 367 Siddiqui MK (e_1_3_7_28_2) 2018; 34 Cohen JA (e_1_3_7_39_2) 2012; 380 Kappos L (e_1_3_7_43_2) 2010; 362 Dias S (e_1_3_7_29_2) 2013; 33 Hauser SL (e_1_3_7_13_2) 2019 Coles AJ (e_1_3_7_40_2) 2012; 380 Calabresi PA (e_1_3_7_33_2) 2014; 13 Jansen JP (e_1_3_7_23_2) 2011; 14 Bornstein MB (e_1_3_7_47_2) 1987; 317 Cree BaC (e_1_3_7_32_2) 2019 O'Connor P (e_1_3_7_46_2) 2009; 8 Fox RJ (e_1_3_7_41_2) 2012; 367 Stępień A (e_1_3_7_55_2) 2013; 20 Moher D (e_1_3_7_20_2) 2009; 151 Lucchetta RC (e_1_3_7_26_2) 2018; 32 Gajofatto A (e_1_3_7_6_2) 2015; 3 Calabrese M (e_1_3_7_48_2) 2012; 18 Vartanian T (e_1_3_7_36_2) 2003; 25 Cohen JA (e_1_3_7_14_2) 2019; 18 Rotstein DL (e_1_3_7_17_2) 2015; 72 e_1_3_7_19_2 Comi G (e_1_3_7_15_2) 2019; 18 Vermersch P (e_1_3_7_61_2) 2014; 20 CAMMS223 Trial Investigators (e_1_3_7_38_2) 2008; 359 Jansen JP (e_1_3_7_24_2) 2013; 11 Khan O (e_1_3_7_52_2) 2013; 73 Lublin FD (e_1_3_7_49_2) 2013; 73 Utz KS (e_1_3_7_18_2) 2014; 7 Confavreux C (e_1_3_7_62_2) 2014; 13 Durelli L (e_1_3_7_34_2) 2002; 359 Cohen JA (e_1_3_7_45_2) 2010; 362 Johnson KP (e_1_3_7_50_2) 1995; 45 Rae-Grant A (e_1_3_7_7_2) 2018; 90 Hoaglin DC (e_1_3_7_22_2) 2011; 14 Jacobs LD (e_1_3_7_54_2) 1996; 39 Polman CH (e_1_3_7_59_2) 2006; 354 e_1_3_7_21_2 Scolding N (e_1_3_7_8_2) 2015; 15 Vollmer TL (e_1_3_7_53_2) 2014; 261 e_1_3_7_25_2 McCool R (e_1_3_7_27_2) 2019; 29 Boiko AN (e_1_3_7_37_2) 2018; 48 Calabresi PA (e_1_3_7_44_2) 2014; 13 Lublin FD (e_1_3_7_4_2) 2014; 83 O'Connor P (e_1_3_7_60_2) 2011; 365 Panitch H (e_1_3_7_57_2) 2002; 59 Merkel B (e_1_3_7_16_2) 2017; 16 Giovannoni G (e_1_3_7_11_2) 2010; 362 IFNB Multiple Sclerosis Study Group (e_1_3_7_58_2) 1993; 43 Borenstein M (e_1_3_7_30_2) 2010; 1 Montalban X (e_1_3_7_10_2) 2018; 24 e_1_3_7_35_2 Ebers GC (e_1_3_7_56_2) 1998; 352 Hauser SL (e_1_3_7_12_2) 2017; 376 Spiegelhalter D (e_1_3_7_31_2) 2004 Marques VD (e_1_3_7_9_2) 2018; 76 Mikol DD (e_1_3_7_51_2) 2008; 7 e_1_3_7_5_2 |
| References_xml | – volume: 1 start-page: 97 issue: 2 year: 2010 ident: e_1_3_7_30_2 article-title: A basic introduction to fixed-effect and random-effects models for meta-analysis publication-title: Res. Synth. Meth. doi: 10.1002/jrsm.12 – volume: 8 start-page: 889 issue: 10 year: 2009 ident: e_1_3_7_46_2 article-title: 250 microg or microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre study publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(09)70226-1 – volume: 376 start-page: 221 issue: 3 year: 2017 ident: e_1_3_7_12_2 article-title: Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1601277 – volume: 11 start-page: 159 issue: 1 year: 2013 ident: e_1_3_7_24_2 article-title: Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers publication-title: BMC Med. doi: 10.1186/1741-7015-11-159 – volume: 24 start-page: 96 issue: 2 year: 2018 ident: e_1_3_7_10_2 article-title: ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis publication-title: Multiple Scler. J. doi: 10.1177/1352458517751049 – volume: 73 start-page: 327 issue: 3 year: 2013 ident: e_1_3_7_49_2 article-title: Randomized study combining interferon and glatiramer acetate in multiple sclerosis publication-title: Ann. Neurol. doi: 10.1002/ana.23863 – volume: 7 start-page: 903 issue: 10 year: 2008 ident: e_1_3_7_51_2 article-title: Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(08)70200-X – volume: 359 start-page: 1786 issue: 17 year: 2008 ident: e_1_3_7_38_2 article-title: Alemtuzumab vs. interferon beta-1a in early multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0802670 – volume: 352 start-page: 1498 issue: 9139 year: 1998 ident: e_1_3_7_56_2 article-title: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis publication-title: Lancet doi: 10.1016/S0140-6736(98)03334-0 – volume: 32 start-page: 813 issue: 9 year: 2018 ident: e_1_3_7_26_2 article-title: Disease-modifying therapies for relapsing–remitting multiple sclerosis: a network meta-analysis publication-title: CNS Drugs doi: 10.1007/s40263-018-0541-5 – volume: 372 start-page: 1502 issue: 9648 year: 2008 ident: e_1_3_7_3_2 article-title: Multiple sclerosis publication-title: Lancet doi: 10.1016/S0140-6736(08)61620-7 – volume: 72 start-page: 152 issue: 2 year: 2015 ident: e_1_3_7_17_2 article-title: Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort publication-title: JAMA Neurol. doi: 10.1001/jamaneurol.2014.3537 – volume: 25 start-page: 105 issue: 1 year: 2003 ident: e_1_3_7_36_2 article-title: An examination of the results of the EVIDENCE, INCOMIN, and Phase III studies of interferon beta products in the treatment of multiple sclerosis publication-title: Clin. Ther. doi: 10.1016/S0149-2918(03)90013-0 – volume: 14 start-page: 417 issue: 4 year: 2011 ident: e_1_3_7_23_2 article-title: Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1 publication-title: Value Health doi: 10.1016/j.jval.2011.04.002 – volume: 76 start-page: 539 year: 2018 ident: e_1_3_7_9_2 article-title: Brazilian consensus for the treatment of multiple sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis publication-title: Arq. Neuropsiquiatr. doi: 10.1590/0004-282x20180078 – volume: 317 start-page: 408 issue: 7 year: 1987 ident: e_1_3_7_47_2 article-title: A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJM198708133170703 – volume: 59 start-page: 1496 issue: 10 year: 2002 ident: e_1_3_7_57_2 article-title: Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial publication-title: Neurology doi: 10.1212/01.WNL.0000034080.43681.DA – volume: 73 start-page: 705 issue: 6 year: 2013 ident: e_1_3_7_52_2 article-title: Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis publication-title: Ann. Neurol. doi: 10.1002/ana.23938 – volume: 354 start-page: 899 issue: 9 year: 2006 ident: e_1_3_7_59_2 article-title: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa044397 – volume: 3 start-page: 545 issue: 7 year: 2015 ident: e_1_3_7_6_2 article-title: Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? publication-title: World J. Clin. Cases doi: 10.12998/wjcc.v3.i7.545 – ident: e_1_3_7_21_2 doi: 10.2217/cer-2020-0122 – volume: 39 start-page: 285 issue: 3 year: 1996 ident: e_1_3_7_54_2 article-title: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis publication-title: Ann. Neurol. doi: 10.1002/ana.410390304 – volume: 362 start-page: 416 issue: 5 year: 2010 ident: e_1_3_7_11_2 article-title: A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0902533 – volume: 18 start-page: 418 issue: 4 year: 2012 ident: e_1_3_7_48_2 article-title: Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis publication-title: Multiple Scler. J. doi: 10.1177/1352458510394702 – volume: 18 start-page: 1021 issue: 11 year: 2019 ident: e_1_3_7_14_2 article-title: Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, Phase III trial publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(19)30238-8 – volume: 45 start-page: 1268 issue: 7 year: 1995 ident: e_1_3_7_50_2 article-title: Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo-controlled trial publication-title: Neurology doi: 10.1212/WNL.45.7.1268 – volume: 33 start-page: 607 issue: 5 year: 2013 ident: e_1_3_7_29_2 article-title: Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials publication-title: Med. Decis. Making doi: 10.1177/0272989X12458724 – volume: 362 start-page: 402 issue: 5 year: 2010 ident: e_1_3_7_45_2 article-title: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0907839 – ident: e_1_3_7_35_2 – ident: e_1_3_7_19_2 – volume: 380 start-page: 1819 issue: 9856 year: 2012 ident: e_1_3_7_39_2 article-title: Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled Phase III trial publication-title: Lancet doi: 10.1016/S0140-6736(12)61769-3 – volume: 151 start-page: 264 issue: 4 year: 2009 ident: e_1_3_7_20_2 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-151-4-200908180-00135 – volume: 20 start-page: 705 issue: 6 year: 2014 ident: e_1_3_7_61_2 article-title: Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled Phase III trial publication-title: Multiple Scler. J. doi: 10.1177/1352458513507821 – volume: 29 start-page: 55 year: 2019 ident: e_1_3_7_27_2 article-title: Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis publication-title: Multiple Scler. Relat. Disord. doi: 10.1016/j.msard.2018.12.040 – volume: 367 start-page: 1087 issue: 12 year: 2012 ident: e_1_3_7_41_2 article-title: Placebo-controlled Phase III study of oral BG-12 or glatiramer in multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1206328 – volume: 90 start-page: 777 issue: 17 year: 2018 ident: e_1_3_7_7_2 article-title: Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology publication-title: Neurology doi: 10.1212/WNL.0000000000005347 – volume: 261 start-page: 773 issue: 4 year: 2014 ident: e_1_3_7_53_2 article-title: A randomized placebo-controlled Phase III trial of oral laquinimod for multiple sclerosis publication-title: J. Neurol. doi: 10.1007/s00415-014-7264-4 – volume-title: Presented at: ECTRIMS 2019. year: 2019 ident: e_1_3_7_13_2 – ident: e_1_3_7_25_2 – volume: 14 start-page: 429 issue: 4 year: 2011 ident: e_1_3_7_22_2 article-title: Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2 publication-title: Value Health doi: 10.1016/j.jval.2011.01.011 – volume: 365 start-page: 1293 issue: 14 year: 2011 ident: e_1_3_7_60_2 article-title: Randomized trial of oral teriflunomide for relapsing multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1014656 – volume: 13 start-page: 657 issue: 7 year: 2014 ident: e_1_3_7_33_2 article-title: Pegylated interferon beta-1a for relapsing–remitting multiple sclerosis (ADVANCE): a randomised, Phase III, double-blind study publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(14)70068-7 – volume: 20 start-page: 213 issue: 4 year: 2013 ident: e_1_3_7_55_2 article-title: Effects of interferon beta-1a and interferon beta-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing–remitting multiple sclerosis: a 3-year longitudinal study publication-title: Neuroimmunomodulation doi: 10.1159/000348701 – volume: 380 start-page: 1829 issue: 9856 year: 2012 ident: e_1_3_7_40_2 article-title: Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled Phase III trial publication-title: Lancet doi: 10.1016/S0140-6736(12)61768-1 – volume: 362 start-page: 387 issue: 5 year: 2010 ident: e_1_3_7_43_2 article-title: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0909494 – volume-title: WinBUGS User Manual. year: 2004 ident: e_1_3_7_31_2 – volume: 83 start-page: 278 issue: 3 year: 2014 ident: e_1_3_7_4_2 article-title: Defining the clinical course of multiple sclerosis: the 2013 revisions publication-title: Neurology doi: 10.1212/WNL.0000000000000560 – volume-title: Presented at: 2019 Consortium of Multiple Sclerosis Centers Annual Meeting. year: 2019 ident: e_1_3_7_32_2 – volume: 367 start-page: 1098 issue: 12 year: 2012 ident: e_1_3_7_42_2 article-title: Placebo-controlled Phase III study of oral BG-12 for relapsing multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1114287 – volume: 43 start-page: 655 issue: 4 year: 1993 ident: e_1_3_7_58_2 article-title: Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial publication-title: Neurology doi: 10.1212/WNL.43.4.655 – volume: 15 start-page: 273 issue: 4 year: 2015 ident: e_1_3_7_8_2 article-title: Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis publication-title: Pract. Neurol. doi: 10.1136/practneurol-2015-001139 – volume: 48 start-page: 351 issue: 3 year: 2018 ident: e_1_3_7_37_2 article-title: A comparative placebo-controlled clinical trial of the efficacy and safety of glatiramer acetate 20 mg in patients with remitting multiple sclerosis: first-year study results publication-title: Neurosci. Behav. Physiol. doi: 10.1007/s11055-018-0570-z – volume: 34 start-page: 1361 issue: 8 year: 2018 ident: e_1_3_7_28_2 article-title: Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis publication-title: Curr. Med. Res. Opin. doi: 10.1080/03007995.2017.1407303 – volume: 359 start-page: 1453 issue: 9316 year: 2002 ident: e_1_3_7_34_2 article-title: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) publication-title: Lancet doi: 10.1016/S0140-6736(02)08430-1 – volume: 13 start-page: 545 issue: 6 year: 2014 ident: e_1_3_7_44_2 article-title: Safety and efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, Phase III trial publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(14)70049-3 – volume: 7 start-page: 263 issue: 6 year: 2014 ident: e_1_3_7_18_2 article-title: Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis publication-title: Ther. Adv. Neurol. Disord. doi: 10.1177/1756285614555335 – volume: 16 start-page: 658 issue: 6 year: 2017 ident: e_1_3_7_16_2 article-title: Timing of high-efficacy therapy in relapsing–remitting multiple sclerosis: a systematic review publication-title: Autoimmun. Rev. doi: 10.1016/j.autrev.2017.04.010 – volume: 13 start-page: 247 issue: 3 year: 2014 ident: e_1_3_7_62_2 article-title: Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, Phase III trial publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(13)70308-9 – ident: e_1_3_7_5_2 – volume: 18 start-page: 1009 issue: 11 year: 2019 ident: e_1_3_7_15_2 article-title: Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, Phase III trial publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(19)30239-X |
| SSID | ssj0000684952 |
| Score | 2.4859757 |
| SecondaryResourceType | review_article |
| Snippet | The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction.... Background: The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse... Background: The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse... |
| SourceID | proquest pubmed crossref futurescience |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 495 |
| SubjectTerms | Antibodies Bans cladribine Cladribine - therapeutic use Classification Clinical trials disease-modifying therapy Drug dosages Humans Meta-analysis Monoclonal antibodies Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy network meta-analysis Neurology ocrelizumab ofatumumab ozanimod Patients Recurrence relapsing multiple sclerosis treatment guidelines |
| SummonAdditionalLinks | – databaseName: Future Medicine (Open Access) dbid: FUMOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fS8MwEA66vQgiir-mUyKITxaXNEnbxyEbQ5hPDvYWmlsKA-3EbQ_-99417WTIXnzoQ0ga0ruk9x13-Y6x-1Qo6TIQEaSmF6nEzyInpIgkOKFnMcRFFS4Yv5rRRL1M9fSXJGk7gi8RLz-B_0JVopNDtZL2WVsmRuMJbA8n49p7Cj_dFKE-xQwkXTgxuI0Do-bfObYs0GGg7qjNzW6YWZmb4TE7qnEi7wfFnrA9X56y_oAIH3L45kCgl7J8KsHyRcE_qqJmPNynQveXz0veZAvyJc6Bi5kvz9hkOHh7HkV1DYQIlOitImK7Rz_SZ5kqVNJzTnhvDCDMR6wi0plHOCZnaHNdkacOstTkmQD0obAvVqDjc9YqF6W_ZByhU5Gj76x8ovEh7SUpALaFAe2gwx4buVioCcKpTsW7RUeBxGhRjJbEaEmMHfawGf4ZmDF2DZRbQrah1eQO7Hqp22jC1qdqaRGLafzyWGH33aYbzwMFOfLSL9Y4hhgQEZZp3WEXQYOb5cVorcmnuvrPiq7ZgaR8liprp8taq6-1v0FAsnK39Wb8AZVt2vM priority: 102 providerName: Future Medicine |
| Title | Efficacy classification of modern therapies in multiple sclerosis |
| URI | http://dx.doi.org/10.2217/cer-2020-0267 https://www.ncbi.nlm.nih.gov/pubmed/33620251 https://www.proquest.com/docview/2515675347 https://www.proquest.com/docview/2492661755 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2042-6313 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000684952 issn: 2042-6305 databaseCode: RPM dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2042-6313 dateEnd: 20210430 omitProxy: true ssIdentifier: ssj0000684952 issn: 2042-6305 databaseCode: BENPR dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection (NC LIVE) customDbUrl: eissn: 2042-6313 dateEnd: 20210430 omitProxy: true ssIdentifier: ssj0000684952 issn: 2042-6305 databaseCode: 7X7 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwEA-6vQgiil_VOSKIT5Ytbfr1JFM2hrAp4mBvpbmmMNB2rtuD_713_ZI9zIdSQtIS7i653-Uud4zd-UJaKgBhgu_2Tenp2FTCEqYFSjixDXZSuAsmU3c8ky9zZ14duOVVWGW9JxYbdZwBnZH3UA87CG5t6T0uv02qGkXe1aqExj5rC4QqJNXe3GvOWPquj_ifHAkW3UJxUbbLNJsWAvEe6BXKCFpPVIRpSy0dlvk8Kh20G3sWOmh0zI4q8MgHJbdP2J5OT9lgSFkgIvjhQEiYQn8KavMs4V9FpTNeXrJCm5gvUl6HEPIc_4GTWeRnbDYafjyPzaowgglS9NcmpcBH41IHgUyk11dKaO26gORBACP8WCNGs2JUxCqJfAWB70aBADSssM-W4NjnrJVmqb5kHPFUEqFBLbXn4EMs9XwAbAsXHAUGe6jpEkKVNZyKV3yGaD0QGUMkY0hkDImMBrtvhi_LdBm7BlpbRA7LVh1QsOujTs2JsFpqefgnGAa7bbpxkZDnI0p1tsExlBYRsZrjGOyi5GAzPRtVOBlaV____JodWBTOUgTtdFhrvdroG8Qja9UthK7L2k_D6ds7vkezyevgF1A24EE |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LTxsxEB5F6YFKVVVEabcEMFLh1BVrr_d1qFAEicLzBFJu7nrWKyG1GyBBFX-qv7Ez-wjiEG4c9mDZa1njsef77PEMwPdUamUzlD6mceDrxBW-lUr6Cq2MihDDsr4uuLyKJzf6bBpNe_CvewvDbpXdnlhv1MUM-Yz8kOxwROA21MnR3b3PWaP4drVLodGoxbl7-kuUbf7z9ITmd1-p8ej6eOK3WQV81DJY-Bw_npiZyzJd6iSwVjoXx0h9k_WXaeEI4KiCrJgt89RilsZ5JpFYCdWFGjlLBG3573QYaI7Vn0yT5ZlOEKfEN_jiQvGrl5jWUhPWUxHwP0T3QDpJbI2TPr0wgx-a-CGtzVuNdWubN_4EH1uwKoaNdq1Dz1UbMBxx1IkcnwQy8mZXo3p2xawUf-rMaqJ51EUcXNxWonNZFHPqgwZzO_8MN28isk3oV7PKfQVB-K3MicBrl0T0sQolKSKVZYyRRQ9-dHIx2EYp52QZvw2xFRajITEaFqNhMXpwsGx-14TnWNVQvRCyaUqdA8OqnwbdTJh2ac_NsyJ6sLespkXJNy155WaP1IbDMBI2jCIPvjQzuBxeSJCBid231zvfhbXJ9eWFuTi9Ot-C94pdaWqHoQH0Fw-Pbpuw0MLu1Aoo4Ndba_x_piAYKw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1JSywxEC5EQQR5KG7jc4mgnmxmkk5vBxFRB3c8KMwtdqrTMKA9Pmfk4V_z11nVy4iH8eahD6HT6VCppL4vqVQB7MZSK5ug9DAOO56OXOZZqaSn0Mog89HPy-OCm9vw_EFf9oLeFHw0d2HYrbJZE8uFOhsg75G3yQ4HBG59HbXz2i3i7rR79PLP4wxSfNLapNOoVOTKvf8n-jY8vDilsd5Tqnt2f3Lu1RkGPNSyM_I4ljyxNJckOtdRx1rpXBgi_YeQgIwzR2BHZWTRbJ7GFpM4TBOJxFDona-RM0bQ8j8T-dpnd7KoF433dzphTNyDDzEU34AJaV5VIT4VkYA2ulfST2JunADqm0mcr2KJ1PZvMu4t7V93Af7UwFUcV5q2CFOuWILjM45AkeK7QEbh7HZUjrQY5OK5zLImqgtexMdFvxCN-6IYUhvUmf5wGR5-RWQrMF0MCrcGgrBcnhKZ1y4K6GF1imJEKssQA4stOGjkYrCOWM6JM54MMRcWoyExGhajYTG2YH9c_aUK1TGpovomZFOVGmeGSR9tNCNh6mk-NF9K2YKd8WuaoHzqkhZu8EZ1OCQj4cQgaMFqNYLj7vkEH5jkrf_c-DbMkq6b64vbq78wp9irpvQd2oDp0eub2yRYNLJbpf4JePxthf8EvlYcZg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+classification+of+modern+therapies+in+multiple+sclerosis&rft.jtitle=Journal+of+comparative+effectiveness+research&rft.au=Samjoo%2C+Imtiaz+A&rft.au=Worthington%2C+Evelyn&rft.au=Drudge%2C+Christopher&rft.au=Zhao%2C+Melody&rft.date=2021-04-01&rft.issn=2042-6313&rft.eissn=2042-6313&rft.volume=10&rft.issue=6&rft.spage=495&rft_id=info:doi/10.2217%2Fcer-2020-0267&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2042-6305&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2042-6305&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2042-6305&client=summon |